Sandostatin LAR (Novartis)
Sandostatin LAR (Novartis) Brand names, Sandostatin LAR (Novartis) Analogs
Sandostatin LAR (Novartis) Brand Names Mixture
- No information avaliable
Sandostatin LAR (Novartis) Chemical_Formula
C49H66N10O10S2.2C2H4O2
Sandostatin LAR (Novartis) RX_link
http://www.rxlist.com/cgi/generic2/octreotide.htm
Sandostatin LAR (Novartis) fda sheet
Sandostatin LAR (Novartis) msds (material safety sheet)
Sandostatin LAR (Novartis) Synthesis Reference
No information avaliable
Sandostatin LAR (Novartis) Molecular Weight
1138.4822
Sandostatin LAR (Novartis) Melting Point
No information avaliable
Sandostatin LAR (Novartis) H2O Solubility
No information avaliable
Sandostatin LAR (Novartis) State
Liquid
Sandostatin LAR (Novartis) LogP
No information avaliable
Sandostatin LAR (Novartis) Dosage Forms
Solution
Sandostatin LAR (Novartis) Indication
For treatment of acromegaly and reduction of side effects from cancer chemotherapy
Sandostatin LAR (Novartis) Pharmacology
Octreotide exerts pharmacologic actions similar to the natural hormone, somatostatin. It is an even more potent inhibitor of growth hormone, glucagon, and insulin than somatostatin. Like somatostatin, it also suppresses leuteinizing hormone (LH) response to GnRH, decreases splanchnic blood flow, and inhibits release of serotonin, gastrin, vasoactive intestinal peptide, secretin, motilin, and pancreatic polypeptide. Octreotide has been used to treat the symptoms associated with metastatic carcinoid tumors (flushing and diarrhea), and Vasoactive Intestinal Peptide (VIP) secreting adenomas (watery diarrhea). Octreotide substantially reduces and in many cases can normalize growth hormone and/or IGF-1 (somatomedin C) levels in patients with acromegaly.
Sandostatin LAR (Novartis) Absorption
No information avaliable
Sandostatin LAR (Novartis) side effects and Toxicity
No information avaliable
Sandostatin LAR (Novartis) Patient Information
No information avaliable
Sandostatin LAR (Novartis) Organisms Affected
Humans and other mammals
